Actively Recruiting
Global Phase 3 Study of Lisaftoclax APG-2575 With Azacitidine in Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
Led by Ascentage Pharma Group Inc. · Updated on 2026-10-13
490
Participants Needed
155
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are conducting a global, multicenter, randomized, double-blind, placebo-controlled pivotal phase III study to evaluate overall survival in patients with newly diagnosed higher-risk myelodysplastic syndrome HR-MDS. The study compares the combination of lisaftoclax APG-2575 and azacitidine AZA against placebo combined with azacitidine. This trial aims to better understand treatment outcomes in this patient group. Participants receive either lisaftoclax orally once daily combined with azacitidine administered by hypodermic or intravenous injection once daily, or placebo orally once daily combined with azacitidine. The study includes two groups running in parallel. Treatment and follow-up continue for up to five years to assess long-term outcomes. During the study, participants will undergo regular evaluations including assessments of overall survival and safety, specifically monitoring adverse events over the five-year period. Participants must be able to complete study procedures and follow-up examinations. The study involves informed consent and ongoing monitoring to ensure participant safety and adherence.
CONDITIONS
Brief Title
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
Research Team
Y
Yifan Zhai, M.D., Ph.D.
Q
Qian Niu, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here